Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia | 9 | 2022 | 179 | 3.940 |
Why?
|
| Community-Acquired Infections | 9 | 2022 | 63 | 2.870 |
Why?
|
| Patient Discharge | 6 | 2023 | 300 | 2.230 |
Why?
|
| Hospitalization | 8 | 2023 | 849 | 1.940 |
Why?
|
| Hospital Medicine | 2 | 2023 | 19 | 1.740 |
Why?
|
| Physicians | 7 | 2021 | 673 | 1.510 |
Why?
|
| Length of Stay | 8 | 2023 | 702 | 1.420 |
Why?
|
| Patient Readmission | 7 | 2023 | 329 | 1.250 |
Why?
|
| Neuroblastoma | 6 | 2017 | 374 | 1.210 |
Why?
|
| Patient Satisfaction | 4 | 2020 | 455 | 1.190 |
Why?
|
| Hospital Mortality | 4 | 2022 | 349 | 1.160 |
Why?
|
| Decision Making | 7 | 2021 | 642 | 1.150 |
Why?
|
| Internship and Residency | 4 | 2022 | 1004 | 0.980 |
Why?
|
| Copyright | 2 | 2013 | 2 | 0.940 |
Why?
|
| Clinical Coding | 2 | 2013 | 23 | 0.920 |
Why?
|
| Medical Overuse | 2 | 2021 | 36 | 0.920 |
Why?
|
| Skilled Nursing Facilities | 1 | 2023 | 41 | 0.910 |
Why?
|
| Cross Infection | 2 | 2021 | 141 | 0.880 |
Why?
|
| Physician-Patient Relations | 5 | 2021 | 610 | 0.860 |
Why?
|
| Respiratory Insufficiency | 2 | 2022 | 150 | 0.830 |
Why?
|
| Comorbidity | 4 | 2018 | 943 | 0.800 |
Why?
|
| Humans | 55 | 2023 | 86643 | 0.800 |
Why?
|
| Medicare | 4 | 2022 | 410 | 0.800 |
Why?
|
| Universal Precautions | 1 | 2021 | 5 | 0.790 |
Why?
|
| Mental Fatigue | 1 | 2021 | 9 | 0.780 |
Why?
|
| United States | 18 | 2022 | 6672 | 0.770 |
Why?
|
| Personal Autonomy | 1 | 2021 | 112 | 0.750 |
Why?
|
| Patient Preference | 2 | 2020 | 105 | 0.740 |
Why?
|
| Sepsis | 2 | 2022 | 306 | 0.720 |
Why?
|
| Hospitalists | 1 | 2021 | 131 | 0.720 |
Why?
|
| Occupational Exposure | 1 | 2020 | 80 | 0.700 |
Why?
|
| Education, Medical, Graduate | 2 | 2013 | 369 | 0.690 |
Why?
|
| Marital Status | 1 | 2019 | 40 | 0.690 |
Why?
|
| Patient Participation | 2 | 2020 | 216 | 0.680 |
Why?
|
| Health Personnel | 1 | 2021 | 202 | 0.670 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 426 | 0.670 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2018 | 18 | 0.660 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 1801 | 0.660 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 33 | 0.660 |
Why?
|
| Splenic Diseases | 1 | 2018 | 16 | 0.660 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 0.640 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.640 |
Why?
|
| Pancreatitis | 1 | 2018 | 87 | 0.630 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2017 | 229 | 0.610 |
Why?
|
| Data Collection | 1 | 2018 | 372 | 0.600 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 65 | 0.590 |
Why?
|
| Colonic Diseases | 1 | 2017 | 65 | 0.580 |
Why?
|
| Gastroenterologists | 1 | 2017 | 30 | 0.580 |
Why?
|
| Mass Screening | 1 | 2021 | 618 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.570 |
Why?
|
| Ambulatory Care | 2 | 2016 | 181 | 0.570 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 241 | 0.560 |
Why?
|
| Communication | 2 | 2016 | 441 | 0.540 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 394 | 0.540 |
Why?
|
| Patient-Centered Care | 4 | 2021 | 203 | 0.520 |
Why?
|
| Colonoscopy | 1 | 2017 | 264 | 0.520 |
Why?
|
| Pandemics | 2 | 2020 | 740 | 0.510 |
Why?
|
| Terminal Care | 1 | 2016 | 130 | 0.510 |
Why?
|
| Logistic Models | 6 | 2019 | 1186 | 0.500 |
Why?
|
| Hospital-Physician Joint Ventures | 1 | 2014 | 3 | 0.500 |
Why?
|
| Constipation | 1 | 2015 | 63 | 0.500 |
Why?
|
| Comprehensive Health Care | 1 | 2014 | 13 | 0.490 |
Why?
|
| Palliative Care | 1 | 2016 | 257 | 0.490 |
Why?
|
| Office Visits | 1 | 2014 | 44 | 0.490 |
Why?
|
| Waiting Lists | 2 | 2015 | 175 | 0.480 |
Why?
|
| Health Status Indicators | 1 | 2014 | 105 | 0.470 |
Why?
|
| Hospital Costs | 1 | 2014 | 105 | 0.460 |
Why?
|
| Critical Care | 1 | 2016 | 370 | 0.450 |
Why?
|
| Male | 24 | 2020 | 40965 | 0.450 |
Why?
|
| Inpatients | 4 | 2022 | 297 | 0.440 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 567 | 0.440 |
Why?
|
| Aged | 17 | 2020 | 18415 | 0.430 |
Why?
|
| Intensive Care Units | 1 | 2015 | 373 | 0.430 |
Why?
|
| Holidays | 1 | 2011 | 4 | 0.420 |
Why?
|
| Wit and Humor as Topic | 1 | 2011 | 13 | 0.420 |
Why?
|
| Hospitals, General | 1 | 2011 | 12 | 0.420 |
Why?
|
| Famous Persons | 1 | 2011 | 14 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 582 | 0.410 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 6509 | 0.410 |
Why?
|
| Teaching Rounds | 1 | 2011 | 24 | 0.410 |
Why?
|
| Middle Aged | 18 | 2020 | 25028 | 0.400 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 32 | 0.390 |
Why?
|
| Art | 1 | 2010 | 6 | 0.380 |
Why?
|
| Search Engine | 1 | 2010 | 9 | 0.380 |
Why?
|
| Female | 22 | 2020 | 44532 | 0.380 |
Why?
|
| Risk Factors | 9 | 2018 | 5417 | 0.370 |
Why?
|
| Adult | 17 | 2022 | 25648 | 0.350 |
Why?
|
| Infection Control | 2 | 2021 | 115 | 0.350 |
Why?
|
| Sex Factors | 4 | 2018 | 1054 | 0.340 |
Why?
|
| Terminology as Topic | 1 | 2010 | 217 | 0.330 |
Why?
|
| Age Factors | 4 | 2018 | 1851 | 0.330 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.320 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 379 | 0.320 |
Why?
|
| Internet | 1 | 2010 | 312 | 0.320 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2017 | 17 | 0.300 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.290 |
Why?
|
| Palmitic Acid | 1 | 2016 | 26 | 0.290 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.290 |
Why?
|
| Acute Disease | 2 | 2021 | 826 | 0.290 |
Why?
|
| Chicago | 4 | 2020 | 1379 | 0.290 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 484 | 0.280 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 127 | 0.280 |
Why?
|
| Antithrombin III Deficiency | 1 | 2005 | 3 | 0.280 |
Why?
|
| Behcet Syndrome | 1 | 2005 | 13 | 0.270 |
Why?
|
| Trisomy | 1 | 2005 | 55 | 0.270 |
Why?
|
| Mosaicism | 1 | 2005 | 67 | 0.270 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 196 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2005 | 85 | 0.270 |
Why?
|
| Genes, myc | 1 | 2015 | 39 | 0.260 |
Why?
|
| Odds Ratio | 3 | 2019 | 678 | 0.260 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 59 | 0.260 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 329 | 0.260 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 79 | 0.260 |
Why?
|
| Obesity | 1 | 2011 | 963 | 0.260 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 322 | 0.250 |
Why?
|
| Risk Assessment | 3 | 2018 | 2261 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2005 | 346 | 0.210 |
Why?
|
| Informed Consent | 2 | 2021 | 266 | 0.200 |
Why?
|
| Occupations | 1 | 2021 | 26 | 0.200 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 55 | 0.200 |
Why?
|
| Goals | 1 | 2021 | 67 | 0.200 |
Why?
|
| Treatment Refusal | 1 | 2021 | 60 | 0.190 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 30 | 0.190 |
Why?
|
| Euthanasia, Passive | 1 | 2000 | 16 | 0.190 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 696 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 645 | 0.190 |
Why?
|
| Patient Advocacy | 1 | 2000 | 49 | 0.190 |
Why?
|
| Suicide, Assisted | 1 | 2000 | 31 | 0.190 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.190 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.190 |
Why?
|
| Lymph Nodes | 1 | 2014 | 533 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 73 | 0.180 |
Why?
|
| Truth Disclosure | 1 | 2000 | 87 | 0.180 |
Why?
|
| Internal Medicine | 2 | 2014 | 347 | 0.180 |
Why?
|
| Attitude | 1 | 2000 | 127 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2014 | 628 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2023 | 8489 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2021 | 220 | 0.170 |
Why?
|
| Workload | 1 | 2020 | 128 | 0.170 |
Why?
|
| Mobility Limitation | 1 | 2019 | 19 | 0.170 |
Why?
|
| Medicaid | 1 | 2022 | 217 | 0.170 |
Why?
|
| Splenic Vein | 1 | 2018 | 5 | 0.170 |
Why?
|
| Gastric Fundus | 1 | 2018 | 7 | 0.170 |
Why?
|
| Pharmacogenetics | 1 | 2022 | 434 | 0.170 |
Why?
|
| Risk Adjustment | 1 | 2018 | 39 | 0.170 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 34 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 763 | 0.160 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1208 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2000 | 306 | 0.160 |
Why?
|
| Prognosis | 3 | 2016 | 3679 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 999 | 0.150 |
Why?
|
| Steroids | 1 | 2018 | 177 | 0.150 |
Why?
|
| Health Services | 1 | 2017 | 55 | 0.150 |
Why?
|
| Negotiating | 1 | 2016 | 19 | 0.140 |
Why?
|
| Transitional Care | 1 | 2016 | 18 | 0.140 |
Why?
|
| Medication Reconciliation | 1 | 2016 | 6 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1621 | 0.140 |
Why?
|
| Home Care Services | 1 | 2017 | 72 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2016 | 2767 | 0.140 |
Why?
|
| Managed Care Programs | 1 | 1996 | 42 | 0.140 |
Why?
|
| Employment | 1 | 1996 | 52 | 0.140 |
Why?
|
| Career Choice | 1 | 1997 | 139 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 636 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 69 | 0.130 |
Why?
|
| Medical Records | 1 | 2015 | 119 | 0.130 |
Why?
|
| Research Design | 1 | 2018 | 594 | 0.130 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2426 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 327 | 0.130 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 164 | 0.130 |
Why?
|
| Pneumonia, Bacterial | 1 | 2014 | 28 | 0.130 |
Why?
|
| Patient Handoff | 1 | 2016 | 93 | 0.130 |
Why?
|
| Empathy | 1 | 2016 | 147 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2501 | 0.120 |
Why?
|
| Cost Control | 1 | 2014 | 44 | 0.120 |
Why?
|
| Health Services Research | 1 | 2014 | 136 | 0.120 |
Why?
|
| Trust | 1 | 2013 | 95 | 0.110 |
Why?
|
| Massachusetts | 1 | 2011 | 33 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2015 | 1538 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 4213 | 0.100 |
Why?
|
| Students, Medical | 1 | 1997 | 384 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2015 | 380 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 1 | 2011 | 28 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1204 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2017 | 7993 | 0.100 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 41 | 0.100 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 48 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2016 | 751 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2011 | 173 | 0.100 |
Why?
|
| Age Distribution | 1 | 2011 | 204 | 0.090 |
Why?
|
| Outpatients | 1 | 2011 | 94 | 0.090 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 89 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2014 | 428 | 0.090 |
Why?
|
| Mortality | 1 | 2011 | 149 | 0.090 |
Why?
|
| Time Factors | 2 | 2018 | 5210 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2011 | 207 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 859 | 0.080 |
Why?
|
| Adolescent | 3 | 2016 | 8981 | 0.080 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2017 | 19 | 0.080 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 56 | 0.080 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.070 |
Why?
|
| Incidence | 1 | 2011 | 1577 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 138 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 180 | 0.070 |
Why?
|
| Specialization | 2 | 1997 | 65 | 0.070 |
Why?
|
| Consensus | 1 | 2017 | 335 | 0.070 |
Why?
|
| Neoplasms | 1 | 2000 | 2898 | 0.070 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2015 | 36 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 5976 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2016 | 342 | 0.060 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 7 | 0.060 |
Why?
|
| Cell Survival | 1 | 2016 | 969 | 0.060 |
Why?
|
| Response Elements | 1 | 2014 | 63 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2014 | 85 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2014 | 68 | 0.060 |
Why?
|
| Quality Control | 1 | 2014 | 117 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2014 | 285 | 0.060 |
Why?
|
| Cytosine | 1 | 2014 | 127 | 0.060 |
Why?
|
| Child | 2 | 2015 | 6927 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 299 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 138 | 0.060 |
Why?
|
| 5-Methylcytosine | 1 | 2014 | 112 | 0.060 |
Why?
|
| Cell Movement | 1 | 2016 | 758 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 151 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1621 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 273 | 0.060 |
Why?
|
| Pharmacists | 1 | 2022 | 32 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1753 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 486 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 547 | 0.050 |
Why?
|
| Pharmacogenomic Testing | 1 | 2022 | 97 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2014 | 712 | 0.050 |
Why?
|
| Heart Failure | 1 | 2011 | 1204 | 0.050 |
Why?
|
| Cross-Cultural Comparison | 1 | 2000 | 34 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 592 | 0.050 |
Why?
|
| Japan | 1 | 2000 | 307 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 479 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 1056 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 1749 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2000 | 227 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1458 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1197 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1939 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 223 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 395 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 66 | 0.040 |
Why?
|
| Infant | 1 | 2014 | 3046 | 0.040 |
Why?
|
| Phenotype | 1 | 2014 | 2378 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2014 | 1351 | 0.040 |
Why?
|
| General Practice | 1 | 2016 | 8 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 220 | 0.040 |
Why?
|
| Medicine | 1 | 1997 | 89 | 0.030 |
Why?
|
| California | 1 | 1996 | 138 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2357 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2271 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 304 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 164 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 193 | 0.030 |
Why?
|
| Perception | 1 | 2015 | 168 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1036 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 112 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2013 | 194 | 0.030 |
Why?
|
| Mice | 1 | 2016 | 11352 | 0.030 |
Why?
|
| Education, Medical | 1 | 1996 | 233 | 0.030 |
Why?
|
| Health Surveys | 1 | 2013 | 239 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 1991 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1830 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 26582 | 0.020 |
Why?
|
| Hyperthermia, Induced | 2 | 1956 | 73 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 2 | 1956 | 179 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1953 | 71 | 0.010 |
Why?
|
| Agglutinins | 1 | 1950 | 4 | 0.010 |
Why?
|
| Typhoid Fever | 1 | 1950 | 4 | 0.010 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1950 | 5 | 0.010 |
Why?
|
| Agglutination | 1 | 1950 | 17 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1950 | 41 | 0.010 |
Why?
|